More articles from Thoracic tumours

1-year mortality in lung cancer in France according to key timepoints of care pathways
Axelle Rivière, Anne Isabelle Lecuyer, Emeline Laurent, Carole Lefebvre, Thierry Lecomte, Elodie Olivier, Delphine Carmier, Laurent Plantier, Leslie Grammatico-Guillon

ERJ Open Research Oct 2022, 8 (4) 00157-2022; DOI: 10.1183/23120541.00157-2022
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken

ERJ Open Research Oct 2022, 8 (4) 00239-2022; DOI: 10.1183/23120541.00239-2022
Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
Emily Pei-Ying Lin, Li-Ching Huang, Jennifer Whisenant, Sally York, Travis Osterman, Jennifer Lewis, Wade Iams, Emily Skotte, Amanda Cass, Chih-Yuan Hsu, Yu Shyr, Leora Horn

ERJ Open Research Oct 2022, 8 (4) 00684-2021; DOI: 10.1183/23120541.00684-2021

Main menu